Tags

Type your tag names separated by a space and hit enter

Effects of oral beraprost sodium, a prostaglandin I2 analogue, on endothelium dependent vasodilatation in the forearm of patients with coronary artery disease.
Clin Exp Pharmacol Physiol. 2006 Apr; 33(4):381-7.CE

Abstract

1. Previous clinical studies with prostaglandin I(2) (PGI(2)) analogue beraprost sodium suggested the potential effects on protection of cardiovascular events in patients with peripheral artery disease. Although the mechanism is not well known, experimental studies have shown protective effects of endothelial cells. This study was designed to examine the effects of beraprost sodium on vascular endothelial function in the forearm of patients with coronary artery disease. 2. Beraprost sodium (120 microg/day) was orally administered to 14 coronary artery disease patients for 4 weeks and then stopped for 4 weeks. Eleven control patients did not receive beraprost sodium treatment. Reactive hyperemia was induced in the forearm, endothelium-dependent vasodilatation was assessed by plethysmography, and urinary 8-iso-prostaglandin F(2alpha) (8-iso-PGF(2alpha)) was measured at baseline, 4 weeks and 8 weeks. 3. Both groups had similar reactive hyperemic responses at baseline. In the control group, reactive hyperemic response and urinary 8-iso-PGF(2alpha) remained unchanged for 8 weeks. In the beraprost group, maximum forearm blood flow increased significantly (P = 0.01) after 4 weeks of treatment and returned to baseline at 8 weeks. Duration of hyperemia increased significantly (P = 0.003) after 4 weeks, and remained greater than baseline at 8 weeks (P = 0.02). Urinary 8-iso-PGF(2alpha) decreased significantly (P = 0.03) after 4 weeks, and tended to be lower at 8 weeks (P = 0.07). Changes in reactive hyperemia correlated weakly but significantly with changes in 8-iso-PGF(2alpha) (P < 0.001). 4. Beraprost sodium decreased oxidative stress and improved forearm endothelium-dependent vasodilatation in coronary artery disease patients. The favorable effects on vascular endothelium could potentially lead to a decrease in vascular events.

Authors+Show Affiliations

Division of Cardiovascular Medicine, Department of Internal Medicine, Shimane University Faculty of Medicine, Izumo City, Shimane, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

16620305

Citation

Ohata, Shuzo, et al. "Effects of Oral Beraprost Sodium, a Prostaglandin I2 Analogue, On Endothelium Dependent Vasodilatation in the Forearm of Patients With Coronary Artery Disease." Clinical and Experimental Pharmacology & Physiology, vol. 33, no. 4, 2006, pp. 381-7.
Ohata S, Ishibashi Y, Shimada T, et al. Effects of oral beraprost sodium, a prostaglandin I2 analogue, on endothelium dependent vasodilatation in the forearm of patients with coronary artery disease. Clin Exp Pharmacol Physiol. 2006;33(4):381-7.
Ohata, S., Ishibashi, Y., Shimada, T., Takahashi, N., Sugamori, T., Sakane, T., Hirano, Y., Oyake, N., Murakami, Y., & Higami, T. (2006). Effects of oral beraprost sodium, a prostaglandin I2 analogue, on endothelium dependent vasodilatation in the forearm of patients with coronary artery disease. Clinical and Experimental Pharmacology & Physiology, 33(4), 381-7.
Ohata S, et al. Effects of Oral Beraprost Sodium, a Prostaglandin I2 Analogue, On Endothelium Dependent Vasodilatation in the Forearm of Patients With Coronary Artery Disease. Clin Exp Pharmacol Physiol. 2006;33(4):381-7. PubMed PMID: 16620305.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of oral beraprost sodium, a prostaglandin I2 analogue, on endothelium dependent vasodilatation in the forearm of patients with coronary artery disease. AU - Ohata,Shuzo, AU - Ishibashi,Yutaka, AU - Shimada,Toshio, AU - Takahashi,Nobuyuki, AU - Sugamori,Takashi, AU - Sakane,Takeshi, AU - Hirano,Yoshifumi, AU - Oyake,Nobuyuki, AU - Murakami,Yo, AU - Higami,Tetsuya, PY - 2006/4/20/pubmed PY - 2006/5/18/medline PY - 2006/4/20/entrez SP - 381 EP - 7 JF - Clinical and experimental pharmacology & physiology JO - Clin. Exp. Pharmacol. Physiol. VL - 33 IS - 4 N2 - 1. Previous clinical studies with prostaglandin I(2) (PGI(2)) analogue beraprost sodium suggested the potential effects on protection of cardiovascular events in patients with peripheral artery disease. Although the mechanism is not well known, experimental studies have shown protective effects of endothelial cells. This study was designed to examine the effects of beraprost sodium on vascular endothelial function in the forearm of patients with coronary artery disease. 2. Beraprost sodium (120 microg/day) was orally administered to 14 coronary artery disease patients for 4 weeks and then stopped for 4 weeks. Eleven control patients did not receive beraprost sodium treatment. Reactive hyperemia was induced in the forearm, endothelium-dependent vasodilatation was assessed by plethysmography, and urinary 8-iso-prostaglandin F(2alpha) (8-iso-PGF(2alpha)) was measured at baseline, 4 weeks and 8 weeks. 3. Both groups had similar reactive hyperemic responses at baseline. In the control group, reactive hyperemic response and urinary 8-iso-PGF(2alpha) remained unchanged for 8 weeks. In the beraprost group, maximum forearm blood flow increased significantly (P = 0.01) after 4 weeks of treatment and returned to baseline at 8 weeks. Duration of hyperemia increased significantly (P = 0.003) after 4 weeks, and remained greater than baseline at 8 weeks (P = 0.02). Urinary 8-iso-PGF(2alpha) decreased significantly (P = 0.03) after 4 weeks, and tended to be lower at 8 weeks (P = 0.07). Changes in reactive hyperemia correlated weakly but significantly with changes in 8-iso-PGF(2alpha) (P < 0.001). 4. Beraprost sodium decreased oxidative stress and improved forearm endothelium-dependent vasodilatation in coronary artery disease patients. The favorable effects on vascular endothelium could potentially lead to a decrease in vascular events. SN - 0305-1870 UR - https://www.unboundmedicine.com/medline/citation/16620305/Effects_of_oral_beraprost_sodium_a_prostaglandin_I2_analogue_on_endothelium_dependent_vasodilatation_in_the_forearm_of_patients_with_coronary_artery_disease_ L2 - https://doi.org/10.1111/j.1440-1681.2006.04379.x DB - PRIME DP - Unbound Medicine ER -